Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.

Wennier ST, Brinkmann K, Steinhäußer C, Mayländer N, Mnich C, Wielert U, Dirmeier U, Hausmann J, Chaplin P, Steigerwald R.

PLoS One. 2013 Aug 12;8(8):e73511. doi: 10.1371/journal.pone.0073511. eCollection 2013.

2.

Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Baur K, Brinkmann K, Schweneker M, Pätzold J, Meisinger-Henschel C, Hermann J, Steigerwald R, Chaplin P, Suter M, Hausmann J.

J Virol. 2010 Sep;84(17):8743-52. doi: 10.1128/JVI.00604-10. Epub 2010 Jun 10.

3.

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.

Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB.

PLoS One. 2009;4(5):e5445. doi: 10.1371/journal.pone.0005445. Epub 2009 May 6.

4.

Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.

García-Arriaza J, Gómez CE, Sorzano CÓ, Esteban M.

J Virol. 2014 Mar;88(6):3392-410. doi: 10.1128/JVI.02723-13. Epub 2014 Jan 3.

5.

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.

Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-Sanz R, Jiménez V, Roger T, Calandra T, Pantaleo G, Esteban M.

PLoS One. 2012;7(10):e48524. doi: 10.1371/journal.pone.0048524. Epub 2012 Oct 31.

6.

A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, Kümmerer BM, Liljeström P, Esteban M.

J Virol. 2014 Mar;88(6):3527-47. doi: 10.1128/JVI.03418-13. Epub 2014 Jan 8.

8.

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.

Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M.

Virus Res. 2006 Mar;116(1-2):11-20. Epub 2005 Oct 7.

PMID:
16214252
9.
10.

Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.

Hanwell DG, McNeil B, Visan L, Rodrigues L, Dunn P, Shewen PE, Macallum GE, Turner PV, Vogel TU.

J Immunother. 2013 May;36(4):238-47. doi: 10.1097/CJI.0b013e3182941813.

PMID:
23603858
12.

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.

García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M.

PLoS One. 2011;6(8):e24244. doi: 10.1371/journal.pone.0024244. Epub 2011 Aug 31.

15.

Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Pérez-Jiménez E, Oliveros JC, Esteban M.

J Virol. 2013 Jun;87(12):6955-74. doi: 10.1128/JVI.03013-12. Epub 2013 Apr 17.

16.

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.

Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, Pinheiro S, Gillespie G, Brown D, Loach V, Roberts J, Guimaraes-Walker A, Hayes P, Loughran K, Smith C, De Bont J, Verlinde C, Vooijs D, Schmidt C, Boaz M, Gilmour J, Fast P, Dorrell L, Hanke T, McMichael AJ.

J Virol. 2006 May;80(10):4717-28.

17.

Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.

Wang Z, La Rosa C, Lacey SF, Maas R, Mekhoubad S, Britt WJ, Diamond DJ.

J Clin Virol. 2006 Mar;35(3):324-31. Epub 2006 Jan 4.

PMID:
16388983
19.

Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA.

Orubu T, Alharbi NK, Lambe T, Gilbert SC, Cottingham MG.

PLoS One. 2012;7(6):e40167. doi: 10.1371/journal.pone.0040167. Epub 2012 Jun 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk